{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:06:35Z","timestamp":1787501195704,"version":"build-2736575974"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:00:00Z","timestamp":1599868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1007\/s10787-020-00753-z","type":"journal-article","created":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T00:03:44Z","timestamp":1599869024000},"page":"35-47","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Effect of canakinumab on clinical and biochemical parameters in acute gouty arthritis: a meta-analysis"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6244-2988","authenticated-orcid":false,"given":"Monalisa","family":"Jena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amruta","family":"Tripathy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8837-299X","authenticated-orcid":false,"given":"Archana","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4063-9178","authenticated-orcid":false,"given":"Rituparna","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,12]]},"reference":[{"key":"753_CR1","doi-asserted-by":"publisher","first-page":"R67","DOI":"10.1186\/ar2438","volume":"10","author":"R Alten","year":"2008","unstructured":"Alten R, Gram H, Joosten LA, van den Berg WB, Sieper J, Wassenberg S et al (2008) The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 10:R67","journal-title":"Arthritis Res Ther"},{"key":"753_CR2","first-page":"2403","volume":"29","author":"E Arromdee","year":"2002","unstructured":"Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE (2002) Epidemiology of gout: is the incidence rising? J Rheumatol 29:2403\u20132406","journal-title":"J Rheumatol"},{"key":"753_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, Rucker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160","journal-title":"Evid Based Ment Health"},{"key":"753_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1006\/cyto.2001.0974","volume":"17","author":"P Berger","year":"2002","unstructured":"Berger P, McConnell JP, Nunn M, Kornman KS, Sorrell J, Stephenson K et al (2002) C-reactive protein levels are influenced by common IL-1 gene variations. Cytokine 17:171\u2013174","journal-title":"Cytokine"},{"key":"753_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/ar2952","volume":"12","author":"N Busso","year":"2010","unstructured":"Busso N, So A (2010) Mechanisms of inflammation in gout. Arthritis Res Ther 12:206","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"753_CR35","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1002\/jcph.162","volume":"53","author":"A Chakraborty","year":"2013","unstructured":"Chakraborty A, Van LM, Skerjanec A, Floch D, Klein UR, Krammer G, Sunkara G, Howard D (2013) Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis. J Clin Pharmacol 53(12):1240\u20131251","journal-title":"J Clin Pharmacol"},{"key":"753_CR6","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40744-017-0063-5","volume":"4","author":"DNV Challa","year":"2017","unstructured":"Challa DNV, Crowson CS, Davis JM 3rd (2017) The patient global assessment of disease activity in rheumatoid arthritis: identification of underlying latent factors. Rheumatol Ther 4:201\u2013208","journal-title":"Rheumatol Ther"},{"key":"753_CR7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2047487313514895","volume":"22","author":"LE Clarson","year":"2015","unstructured":"Clarson LE, Chandratre P, Hider SL, Belcher J, Heneghan C, Roddy E et al (2015) Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 22:335\u2013343","journal-title":"Eur J Prev Cardiol"},{"key":"753_CR8","unstructured":"Cumulative Distribution Function (CDF) (2020) Calculator for the t-Distribution [Software]. [Online]. https:\/\/www.danielsoper.com\/statcalc"},{"key":"753_CR9","unstructured":"GRADEpro GDT (2015) GRADEpro Guideline Development Tool [Software]. [Online]. https:\/\/gradepro.org"},{"key":"753_CR10","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/ar2659","volume":"11","author":"LR Harrold","year":"2009","unstructured":"Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA et al (2009) Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 11:R46","journal-title":"Arthritis Res Ther"},{"key":"753_CR36","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1111\/ijcp.12521","volume":"68","author":"JD Hirsch","year":"2014","unstructured":"Hirsch JD, Gnanasakthy A, Lale R, Choi K, Sarkin AJ (2014) Efficacy of Canakinumab vs. triamcinolone acetonide according to multiple gouty arthritis-related health outcomes measures. Int J Clini Pract 68 (12):1503\u20131507","journal-title":"Int J Clini Pract"},{"key":"753_CR11","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","volume":"46","author":"KM Jordan","year":"2007","unstructured":"Jordan KM, Cameron JS, Snaith M, Zhang W, Doherty M, Seckl J et al (2007) British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 46:1372\u20131374","journal-title":"Rheumatology (Oxford)"},{"key":"753_CR12","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1002\/acr.21773","volume":"64","author":"D Khanna","year":"2012","unstructured":"Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T et al (2012) 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 64:1447\u20131461","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"753_CR13","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.semarthrit.2014.02.003","volume":"44","author":"PP Khanna","year":"2014","unstructured":"Khanna PP, Gladue HS, Singh MK, FitzGerald JD, Bae S, Prakash S et al (2014) Treatment of acute gout: a systematic review. Semin Arthritis Rheum 44:31\u201338","journal-title":"Semin Arthritis Rheum"},{"key":"753_CR14","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/j.1524-4733.2007.00173.x","volume":"10","author":"NL Kleinman","year":"2007","unstructured":"Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE et al (2007) The impact of gout on work absence and productivity. Value Health 10:231\u2013237","journal-title":"Value Health"},{"key":"753_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/rheumatology\/kep364","volume":"49","author":"CF Kuo","year":"2010","unstructured":"Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS et al (2010) Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 49:141\u2013146","journal-title":"Rheumatology (Oxford)"},{"key":"753_CR16","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1111\/j.0105-2896.2009.00860.x","volume":"233","author":"F Martinon","year":"2010","unstructured":"Martinon F (2010) Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 233:218\u2013232","journal-title":"Immunol Rev"},{"key":"753_CR17","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature04516","volume":"440","author":"F Martinon","year":"2006","unstructured":"Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J (2006) Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440:237\u2013241","journal-title":"Nature"},{"key":"753_CR18","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","volume":"6","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097","journal-title":"PLoS Med"},{"key":"753_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P et al (2015) Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 4:1","journal-title":"Syst Rev"},{"key":"753_CR20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1002\/ijc.26077","volume":"129","author":"M Moriya","year":"2011","unstructured":"Moriya M, Slade N, Brdar B, Medverec Z, Tomic K, Jelakovic B et al (2011) TP53 mutational signature for aristolochic acid: an environmental carcinogen. Int J Cancer 129:1532\u20131536","journal-title":"Int J Cancer"},{"key":"753_CR21","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1056\/NEJMcp1001124","volume":"364","author":"T Neogi","year":"2011","unstructured":"Neogi T (2011) Clinical practice. Gout N Engl J Med 364:443\u2013452","journal-title":"Gout N Engl J Med"},{"key":"753_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1001\/jamadermatol.2014.3513","volume":"151","author":"VL Pascoe","year":"2015","unstructured":"Pascoe VL, Enamandram M, Corey KC, Cheng CE, Javorsky EJ, Sung SM et al (2015) Using the Physician Global Assessment in a clinical setting to measure and track patient outcomes. JAMA Dermatol 151:375\u2013381","journal-title":"JAMA Dermatol"},{"key":"753_CR23","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","volume":"10","author":"AA Riedel","year":"2004","unstructured":"Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG (2004) Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 10:308\u2013314","journal-title":"J Clin Rheumatol"},{"key":"753_CR24","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1136\/ard.2010.128454","volume":"69","author":"N Schlesinger","year":"2010","unstructured":"Schlesinger N, Thiele RG (2010) The pathogenesis of bone erosions in gouty arthritis. Ann Rheum Dis 69:1907\u20131912","journal-title":"Ann Rheum Dis"},{"key":"753_CR25","doi-asserted-by":"publisher","first-page":"R53","DOI":"10.1186\/ar3297","volume":"13","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V et al (2011a) Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-to-treat Gouty Arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 13:R53","journal-title":"Arthritis Res Ther"},{"key":"753_CR26","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1136\/ard.2010.144063","volume":"70","author":"N Schlesinger","year":"2011","unstructured":"Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U et al (2011b) Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 70:1264\u20131271","journal-title":"Ann Rheum Dis"},{"key":"753_CR27","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1136\/annrheumdis-2011-200908","volume":"71","author":"N Schlesinger","year":"2012","unstructured":"Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:1839\u20131848","journal-title":"Ann Rheum Dis"},{"key":"753_CR28","doi-asserted-by":"crossref","unstructured":"Schwarzer G (2007) meta: an R Package for meta-analysis, vol 7","DOI":"10.32614\/CRAN.package.meta"},{"key":"753_CR29","doi-asserted-by":"publisher","first-page":"R101","DOI":"10.1186\/ar4281","volume":"15","author":"CA Scire","year":"2013","unstructured":"Scire CA, Manara M, Cimmino MA, Govoni M, Salaffi F, Punzi L et al (2013) Gout impacts on function and health-related quality of life beyond associated risk factors and medical conditions: results from the KING observational study of the Italian Society for Rheumatology (SIR). Arthritis Res Ther 15:R101","journal-title":"Arthritis Res Ther"},{"key":"753_CR30","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/ar2509","volume":"10","author":"A So","year":"2008","unstructured":"So A (2008) Developments in the scientific and clinical understanding of gout. Arthritis Res Ther 10:221","journal-title":"Arthritis Res Ther"},{"key":"753_CR31","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1002\/art.27600","volume":"62","author":"A So","year":"2010","unstructured":"So A, De Meulemeester M, Pikhlak A, Yucel AE, Richard D, Murphy V et al (2010) Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study. Arthritis Rheum 62:3064\u20133076","journal-title":"Arthritis Rheum"},{"key":"753_CR32","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/jrsm.1260","volume":"8","author":"R Suurmond","year":"2017","unstructured":"Suurmond R, van Rhee H, Hak T (2017) Introduction, comparison, and validation of meta-essentials: a free and simple tool for meta-analysis. Res Synth Methods 8:537\u2013553","journal-title":"Res Synth Methods"},{"key":"753_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/annrheumdis-2011-201254","volume":"72","author":"G Trifiro","year":"2013","unstructured":"Trifiro G, Morabito P, Cavagna L, Ferrajolo C, Pecchioli S, Simonetti M et al (2013) Epidemiology of gout and hyperuricaemia in Italy during the years 2005\u20132009: a nationwide population-based study. Ann Rheum Dis 72:694\u2013700","journal-title":"Ann Rheum Dis"},{"key":"753_CR34","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1136\/ard.2006.055269","volume":"65","author":"W Zhang","year":"2006","unstructured":"Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P et al (2006) EULAR evidence based recommendations for gout. Part II: management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 65:1312\u20131324","journal-title":"Ann Rheum Dis"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00753-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-020-00753-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-020-00753-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T14:09:56Z","timestamp":1723558196000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-020-00753-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,12]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["753"],"URL":"https:\/\/doi.org\/10.1007\/s10787-020-00753-z","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,12]]},"assertion":[{"value":"5 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Authors are responsible for the correctness of the statements provided in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All data generated or analysed during this study are included in this published article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}}]}}